NEW YORK, October 18, 2021 – KAISPE in collaboration with ITNextDoor automates the Antigen Testing results distribution process for Tessa Therapeutics Ltd using Microsoft Power Platform and Microsoft 365. This will help Tessa to get the real time result notifications for each employee using SMS and summary reports every weekend via email. Employees upload their Antigen Rapid Test (ART) results via PowerApps app and Power Automate flow uses these results for further distribution.  With this automation, Tessa has gained 80% efficiency to take appropriate workplace health and safety measures on any positive test report(s).

Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer. Tessa’s state-of-the-art GMP cell therapy manufacturing facility, expected to be ready in 2021, will substantially enhance in-house production capabilities and ensure that patients can benefit from our cell therapies more rapidly.

At KAISPE, we pride ourselves on our innovation, expertise, and our continued commitment to ensuring delivery of the highest quality products to our customers. As a Microsoft Certified Partner, we provide solutions backed by industry best practices and standards. We are Microsoft Co-Sell partner and have strong presence on Microsoft marketplaces with our remarkable apps and services.

To learn more, visit https://www.kaispe.com or call (315) 791-4472. Connect with us on Twitter, LinkedIn, and Facebook.